Immunocore Holdings plc Increase Decrease In Operating Lease Liability
Immunocore Holdings plc (IMCR) reported Increase Decrease In Operating Lease Liability of -$2.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Immunocore Holdings plc increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.36M.
- Immunocore Holdings plc increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$864.00K, a 214.29% decline year-over-year.
- Immunocore Holdings plc increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$2.62M.
- Immunocore Holdings plc increase decrease in operating lease liability for the quarter ending 2025-09-30 was $1.05M.
- Immunocore Holdings plc increase decrease in operating lease liability for fiscal 2025 was -$2.09M.
- Immunocore Holdings plc increase decrease in operating lease liability for fiscal 2024 was -$1.65M.
- Immunocore Holdings plc increase decrease in operating lease liability for fiscal 2023 was -$2.23M.
- Immunocore Holdings plc increase decrease in operating lease liability for fiscal 2022 was -$1.78M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.22M 10-Q · filed 2026-08-06 | -$4.84M derived: sum of 3 quarters · filed 2026-08-06 | -$3.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$864.00K 10-Q · filed 2026-05-06 | -$3.48M derived: sum of 2 quarters · filed 2026-05-06 | -$2.43M derived: sum of 3 quarters · filed 2026-05-06 | -$3.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.56M derived: sum of 2 quarters · filed 2026-02-25 | -$2.85M derived: sum of 3 quarters · filed 2026-08-06 | -$2.09M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$232.00K derived: sum of 2 quarters · filed 2026-08-06 | $524.00K 10-Q · filed 2025-11-06 | $84.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$528.00K 10-Q · filed 2026-08-06 | -$968.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $756.00K 10-Q · filed 2026-05-06 | $316.00K derived: sum of 2 quarters · filed 2026-05-06 | $244.00K derived: sum of 3 quarters · filed 2026-05-06 | -$402.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$440.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$512.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.16M derived: sum of 3 quarters · filed 2026-02-25 | -$1.65M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$718.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.21M 10-Q · filed 2025-11-06 | -$4.08M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$646.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.14M 10-Q · filed 2025-08-07 | -$4.01M derived: sum of 3 quarters · filed 2026-02-25 | -$2.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$490.00K 10-Q · filed 2025-05-07 | -$3.36M derived: sum of 2 quarters · filed 2026-02-25 | -$1.81M derived: sum of 3 quarters · filed 2026-02-25 | -$2.23M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.32M derived: sum of 2 quarters · filed 2026-02-25 | -$1.74M derived: sum of 3 quarters · filed 2026-02-25 | -$2.23M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.13M derived: sum of 2 quarters · filed 2024-11-06 | $645.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$906.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$482.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$1.78M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$2.01M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |